Search results for "SUPPRESSION"

showing 10 items of 404 documents

Systemic immunosuppression in times of COVID‐19: Do we need to rethink our standards?

2020

Summary The current SARS‐CoV‐2 pandemic particularly endangers older people with pre‐existing cardiopulmonary and metabolic conditions. However, it is also currently under discussion whether patients under immunosuppressive therapy also have a higher risk of suffering a severe course of the COVID‐19 disease. In principle though, there is currently no data available for a general reduction or pause of immunosuppression in patients with autoimmune diseases because of the SARS‐CoV‐2 pandemic. However, since there is currently neither an effective therapy nor corresponding vaccination protection, the indication for a prolonged immunosuppressive therapy should be made with special care. In parti…

medicine.medical_specialtymedicine.medical_treatment610 MedizinDiseaseReviewDermatologyAntiviral Agents030207 dermatology & venereal diseases03 medical and health sciences0302 clinical medicineChloroquine610 Medical sciencesPandemicMedicineHumansIntensive care medicineImmunosuppression Therapybusiness.industryCOVID-19HydroxychloroquineImmunosuppressionChloroquineCOVID-19 Drug TreatmentCalcineurinVaccinationDoxycyclineRituximabbusinessmedicine.drugHydroxychloroquineJDDG: Journal der Deutschen Dermatologischen Gesellschaft
researchProduct

Antimicrobial prophylaxis in allogeneic bone marrow transplantation. Guidelines of the Infectious Diseases Working Party (AGIHO) of the German Societ…

2005

Patients undergoing allogeneic stem cell transplantation are at high risk for infection with a variety of pathogens during different phases of the procedure. Bacteria and fungi predominate the first phase until engraftment. During the second phase, from engraftment to about day 100, major infectious problems are caused by fungi and cytomegalovirus. Both pathogens remain important under continued immunosuppression, however, in the late post-transplantation period infections with encapsulated bacteria may become a problem. In this review the Infectious Diseases Working Party of the DGHO gives recommendations for prophylaxis of infections under allogeneic stem cell transplantation with drugs a…

medicine.medical_specialtymedicine.medical_treatmentCongenital cytomegalovirus infectionHematopoietic stem cell transplantationNeutropenia03 medical and health sciences0302 clinical medicineAnti-Infective AgentsmedicineHumansTransplantation HomologousInfection controlAntibiotic prophylaxisIntensive care medicineBone Marrow TransplantationInfection Controlbusiness.industryImmunosuppressionHematologyAntibiotic ProphylaxisAntimicrobialmedicine.disease3. Good healthTransplantationOncology030220 oncology & carcinogenesisImmunologyPreventive Medicinebusiness030215 immunologyAnnals of Oncology
researchProduct

Amyloidosis in Inflammatory Bowel Disease: A Systematic Review of Epidemiology, Clinical Features, and Treatment.

2015

Background and Aims: Amyloidosis is a rare complication of inflammatory bowel disease [IBD]; its low prevalence has hindered both descriptive and therapeutic studies. The aim of this study was to estimate the prevalence of amyloidosis in IBD and the risk factors associated with this complication. Methods: This paper presents an observational study, followed by a systematic review of the epidemiological and clinical characteristics of the disease and a review of the diagnostic and therapeutic options. Results: The prevalence of amyloidosis among IBD patients is 0.53% (95% confidence interval [CI]: 0.32–0.75), although epidemiological data suggest that it may be under-diagnosed. The phenotype…

medicine.medical_specialtymedicine.medical_treatmentDiseaseInflammatory bowel disease03 medical and health sciences0302 clinical medicineRisk FactorsInternal medicineEpidemiologymedicinePrevalenceHumansProteinuriabusiness.industryAmyloidosisGastroenterologyImmunosuppressionGeneral MedicineAmyloidosismedicine.diseaseInflammatory Bowel DiseasesSurgeryPhenotypeTreatment Outcome030220 oncology & carcinogenesis030211 gastroenterology & hepatologyObservational studymedicine.symptomComplicationbusinessJournal of Crohn'scolitis
researchProduct

Peripherally Circulating CD4+ FOXP3+ CXCR3+ T Regulatory Cells Correlate with Renal Allograft Function

2012

Peripheral immunoregulation depends on T regulatory cell trafficking into the allograft to modulate the local alloresponse. Little is known about the relevance of trafficking receptors for Tregs after solid organ transplantation in humans. In this study, expression of the peripheral chemokine receptors CXCR3 and CCR5 on CD4+ FOXP3+ Treg cells was analysed and correlated with allograft function in renal transplant recipients. Flow cytometry analysis of peripheral blood mononuclear cells of 54 renal transplant recipients receiving a calcineurin inhibitor-based immunosuppression was performed for CD4, CD25, FOXP3, CXCR3 and CCR5 within the first 18 months post-transplantation. Correlation anal…

medicine.medical_treatmentImmunologyFOXP3hemic and immune systemschemical and pharmacologic phenomenaImmunosuppressionGeneral MedicineBiologyCXCR3Peripheral blood mononuclear cellCalcineurinChemokine receptorImmunologymedicineIL-2 receptorReceptorScandinavian Journal of Immunology
researchProduct

Guillain-Barré syndrome after orthotopic liver transplantation: A clinical manifestation of immune reconstitution inflammatory syndrome?

2018

Guillain-Barrè Syndrome, as part of the spectrum of dysimmune neuropathies, is unexpected to occur in immunocompromised hosts. We describe a clinical case of Guillain-Barrè syndrome, occurred a few weeks after a liver transplant, and we postulate that our case would satisfy all requirements to explain this peripheral nervous system complication as a clinical manifestation of an Immune reconstitution inflammatory syndrome. In this setting of liver transplantation, complicated by potentially multiple infective triggers, reduction of immunosuppression and reversal of pathogen-induced immunosuppression, through antimicrobial therapy, may have led to pro-inflammatory response. The pro-inflammato…

medicine.medical_treatmentLiver transplantationGuillain-Barre SyndromeTacrolimus030207 dermatology & venereal diseases03 medical and health sciences0302 clinical medicineImmune systemImmune reconstitution inflammatory syndromemedicineHumansImmune reconstitution inflammatory syndromeAcute demyelinating polyneuropathyImmunosuppression TherapyInflammationLiver transplantationGuillain-Barre syndromebusiness.industryImmunosuppressionGeneral Medicinemedicine.diseaseGuillain-Barré syndromeTacrolimusPathophysiologyTacrolimuImmunologyAcute demyelinating polyneuropathy; Guillain-Barré syndrome; Immune reconstitution inflammatory syndrome; Liver transplantation; TacrolimusSurgeryFemaleNeurology (clinical)Complicationbusiness030217 neurology & neurosurgery
researchProduct

T cell–mediated response to SARS‐CoV‐2 in liver transplant recipients with prior COVID‐19

2021

Abstract Whether immunosuppression impairs severe acute respiratory syndrome coronavirus 2‐specific T‐cell‐mediated immunity (SARS‐CoV‐2‐CMI) after liver transplantation (LT) remains unknown. We included 31 LT recipients in whom SARS‐CoV‐2‐CMI was assessed by intracellular cytokine staining (ICS) and interferon (IFN)‐γ FluoroSpot assay after a median of 103 days from COVID‐19 diagnosis. Serum SARS‐CoV‐2 IgG antibodies were measured by ELISA. A control group of non‐transplant immunocompetent patients were matched (1:1 ratio) by age and time from diagnosis. Post‐transplant SARS‐CoV‐2‐CMI was detected by ICS in 90.3% (28/31) of recipients, with higher proportions for IFN‐γ‐producing CD4+ than …

medicine.medical_treatmentT cellT-LymphocytesLiver transplantationAntibodies ViralCOVID-19 TestingAntigenImmunityImmunology and AllergyMedicineHumansPharmacology (medical)Transplantationbiologybusiness.industrySARS-CoV-2COVID-19ImmunosuppressionOriginal ArticlesTransplant RecipientsLiver Transplantationmedicine.anatomical_structureImmunologybiology.proteinOriginal ArticleAntibodybusinessFluoroSpotCD8American Journal of Transplantation
researchProduct

Is COVID‐19 infection more severe in kidney transplant recipients?

2021

International audience; There are no studies which have compared the risk of severe Covid-19 and related mortality between transplant recipients and non-transplant patients. We enrolled two groups of patients hospitalized for Covid-19, i.e., kidney transplant recipients from the French Registry of Solid Organ Transplant (n=306) and a single-center cohort of non-transplant patients (n=795). An analysis was performed among subgroups matched for age and risk factors for severe Covid-19 or mortality. Severe Covid-19 was defined as admission (or transfer) to an intensive care unit, need for mechanical ventilation, or death.Transplant recipients were younger and had more comorbidities compared to…

medicine.medical_treatment[SDV]Life Sciences [q-bio]MESH: Registries*AucunMESH: Comorbidity030230 surgerylaw.inventionchemistry.chemical_compound0302 clinical medicinelawcardiovascular diseaseMESH: Risk Factors[SDV.MHEP.MI]Life Sciences [q-bio]/Human health and pathology/Infectious diseasesclinical research / practiceImmunology and AllergyCumulative incidencePharmacology (medical)kidney transplantation / nephrologyMESH: IncidenceMESH: AgedUnivariate analysisMESH: France / epidemiologyMESH: Middle AgedMESH: Transplant Recipients / statistics & numerical data*Acute kidney injuryIntensive care unit3. Good healthMESH: COVID-19 / epidemiologyCohort[SDV.MHEP.MI] Life Sciences [q-bio]/Human health and pathology/Infectious diseasesglomerular filtration rate (GFR)kidney failure / injurymedicine.medical_specialtyinfection and infectious agents - viralinfectious diseaseBrief CommunicationMESH: Graft Rejection / prevention & control03 medical and health sciencesInternal medicineDiabetes mellitusMESH: Severity of Illness IndexMESH: COVID-19 / diagnosis*medicineHumansMESH: SARS-CoV-2Mechanical ventilationCreatinineTransplantationMESH: Humansbusiness.industrySARS-CoV-2MESH: Graft Rejection / epidemiology*COVID-19MESH: Retrospective Studiesmedicine.diseaseKidney TransplantationTransplant RecipientsMESH: Maleimmunosuppressive regimensMESH: Immunosuppressive Agents / therapeutic useMESH: Pandemics*MESH: Propensity Score*chemistryReinfectionMESH: Immunosuppression / methodsMESH: Intensive Care UnitsbusinessMESH: FemaleMESH: Kidney Transplantation*
researchProduct

Poly(I:C) and CpG-ODN combined aerosolization to treat lung metastases and counter the immunosuppressive microenvironment.

2015

The immunostimulatory ability of synthetic oligonucleotides containing CpG motifs (CpG-ODN), agonists of Toll-like receptor 9 (TLR9), can be harnessed to promote antitumor immunity by their application at the tumor site to stimulate local activation of innate immunity; however, particularly in the lung, tumor-associated immunosuppression can subvert such antitumor innate immune responses. To locally maintain continuous activation of innate subpopulations while inhibiting immunosuppressive cells, we evaluated aerosol delivery CpG-ODN combined with Poly(I:C), a TLR3 agonist able to convert tumor-supporting macrophages to tumoricidal effectors, in the treatment of B16 melanoma lung metastases …

miceCpG Oligodeoxynucleotidemedicine.medical_treatmentDacarbazineImmunologySettore MED/08 - Anatomia Patologicaaerosol delivery; dacarbazin; lung metastases; mice; TLR agonists; Immunology and Allergy; Oncology; Immunologylung metastaseMedicineCytotoxic T cellImmunology and AllergyTLR agonistAerosolizationOriginal ResearchInnate immune systembusiness.industryTLR9Immunosuppressionhemic and immune systemsrespiratory systemOncologydacarbazinTLR3ImmunologyCancer researchaerosol deliverybusinessmedicine.drug
researchProduct

2020

The biological anakinra appears promising to halt cytokine storm syndrome seen in severe courses of COVID-19. However, immunosuppression with anakinra may facilitate sepsis, necessitating continuous screening for bacterial superinfections.

musculoskeletal diseasesAnakinra2019-20 coronavirus outbreakARDSCoronavirus disease 2019 (COVID-19)medicine.drug_classbusiness.industrymedicine.medical_treatmentImmunosuppressionGeneral Medicine030204 cardiovascular system & hematologymedicine.diseaseReceptor antagonistSepsis03 medical and health sciences0302 clinical medicine030220 oncology & carcinogenesisImmunologymedicineCytokine stormbusinessmedicine.drugClinical Case Reports
researchProduct

Glucocorticoid-sensitive hereditary inclusion body myositis.

1996

We report a hereditary muscle disorder with features of inclusion body myositis (IBM) in two adult sisters with slowly progressive asymmetrical muscle weakness. The findings of light microscopic and ultrastructural investigations of muscle biopsy specimens were consistent with a diagnosis of IBM. Both patients improved and stabilized on immunosuppressive treatment with corticosteroids and azathioprine. This differentiates our patients from other sporadic and familial cases of IBM. Clinical and histological features are described and compared with those of other previously reported families with IBM.

musculoskeletal diseasesPathologymedicine.medical_specialtyNeurologyeducationMuscle Fibers SkeletalAzathioprineMuscle disorderMyositis Inclusion Bodyparasitic diseasesmedicineHumansGlucocorticoidsMyositisImmunosuppression TherapyMuscle biopsymedicine.diagnostic_testbusiness.industryMuscle weaknessMiddle Agedmedicine.diseasePrognosisMicroscopy ElectronNeurologyFemaleNeurology (clinical)medicine.symptomInclusion body myositisbusinessGlucocorticoidmedicine.drugJournal of neurology
researchProduct